((自动化翻译由路透提供，请见免责声明 ))
12月2日 - ** PTC Therapeutics 股价盘前上涨20.5%至52.89美元
** 该公司称制药商诺华 将为PTCT的候选药物PTC518支付10亿美元预付款和最多19亿美元的里程碑付款，该药物正在开发中，用于治疗亨廷顿氏症
** NOVN 将负责该药物的开发、生产和商业化。
** PTCT 和 NOVN 将分别按 40/60 的比例分享该药物在美国的利润和损失
** 截至上一交易日收盘，股价累计上涨 59.2
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.